Cost Effectiveness of TNF-α Inhibitors in Rheumatoid Arthritis
| العنوان: | Cost Effectiveness of TNF-α Inhibitors in Rheumatoid Arthritis |
|---|---|
| المؤلفون: | Lilian M. Azzopardi, Cynthia Said, Anthony Serracino Inglott, Bernard Coleiro, Maurice Zarb Adami |
| المصدر: | International Journal of Inflammation, Vol 2013 (2013) International Journal of Inflammation |
| بيانات النشر: | Hindawi Publishing Corporation, 2013. |
| سنة النشر: | 2013 |
| مصطلحات موضوعية: | musculoskeletal diseases, medicine.medical_specialty, Article Subject, Cost effectiveness, MEDLINE, Etanercept, Rheumatoid arthritis -- Case studies, Quality of life, Internal medicine, Adalimumab, lcsh:Pathology, Immunology and Allergy, Medicine, skin and connective tissue diseases, business.industry, medicine.disease, Infliximab, humanities, Tnf α inhibitors, Rheumatoid arthritis, Clinical Study, business, Patients -- Care, medicine.drug, lcsh:RB1-214, Tumor necrosis factor -- Receptors |
| الوصف: | Background. TNF-𝛼 inhibitors have shown to be effective in reducing disease activity and improving the quality of life. Due to the high costs associated with acquisition of this treatment, this study was undertaken to evaluate the ICER of TNF-𝛼 antagonists (etanercept, adalimumab, and infliximab) in improving the quality of life. Methods.The HAQ and SF-36 were administered at phases 1, 2, and 3, in order to assess the improvement in the QOL. Suppression of disease activity was assessed through the DAS-28. Results. Statistically significant improvements (𝑃 < 0.05) were noted for the SF-36 and HAQ after 3 months and for the DAS-28 after 6 months of TNF-𝛼 inhibitor therapy.The mean ICER per 10% improvement in the HAQ, DAS-28, and SF-6D were C1976.5, C2086.5, and C2316.4, respectively, following 6 months of TNF-𝛼 intervention. Most favorable ICERs were reported from a patient who had to undergo surgical intervention whilst on DMARD therapy. Conclusion. Significant improvement was observed in patients’ quality of life, after a short timeframe of 6 months. Such data is useful information in the light of convincing policy makers, in terms of providing access to the medications to individual patients on national health service schemes. peer-reviewed |
| وصف الملف: | text/xhtml |
| اللغة: | English |
| تدمد: | 2090-8040 |
| DOI: | 10.1155/2013/581409 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9fbb818e303be3b2d85979f209260c02Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....9fbb818e303be3b2d85979f209260c02 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 20908040 |
|---|---|
| DOI: | 10.1155/2013/581409 |